HPV and Breast Cancer: Examining the Emerging Evidence

Human papillomavirus (HPV) is established as causal for cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers. Its role in breast cancer remains under investigation.

Current Evidence

• Multiple studies detect high-risk HPV DNA (types 16, 18) in breast tumor tissue more frequently than in normal adjacent tissue or benign biopsies.
• Meta-analyses report pooled odds ratios ~3–5 for HPV-positive vs. HPV-negative breast cancer, but heterogeneity is high.
• Large 2017 JAMA Oncology study (1,000+ cases/controls) found HPV DNA associated with increased risk, though absolute risk remained low.
• Mechanistic plausibility: HPV E6/E7 oncoproteins degrade p53 and pRb, disrupting cell-cycle control in breast epithelium.

Limitations and Controversies

• Contamination risk: HPV is ubiquitous; sensitive PCR may detect transient/environmental DNA.
• Confounding: Sexual behavior correlates with both HPV exposure and other breast-cancer risk factors (alcohol, parity, hormonal exposure).
• No prospective cohort proves HPV precedes breast carcinogenesis.
• Major bodies (IARC, ACS, NCCN) do not list HPV as a breast-cancer risk factor.

Practical Implications

• HPV vaccination (Gardasil 9) remains recommended for cervical/oropharyngeal cancer prevention; potential breast benefit is unproven but biologically plausible.
• Standard breast-cancer screening (mammography, MRI for high risk) unchanged.
• Safe sexual practices reduce HPV acquisition overall.

Research continues; for now, HPV is a candidate cofactor, not an established cause of breast cancer.